221. Anti-glomerular basement membrane disease
[
1 clinical trial,
1 drug（DrugBank:
1 drug),
0 target gene / 0 target pathway ]
Searched query = "Anti glomerular basement membrane disease"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03157037 | March 1, 2017 | 16 December 2017 | An Open-Label Phase II Study to Evaluate the Efficacy and Safety of IdeS in Anti-GBM Disease (GOOD-IDES) | An Open-Label Phase II Study in Anti-GBM Disease (Goodpasture's Disease) With Adverse Renal Prognosis to Evaluate the Efficacy and Safety of IdeS --GOOD-IDES | Anti-Glomerular Basement Membrane Disease | Biological: HMed-IdeS | Mårten Segelmark | Hansa Medical AB | Recruiting | 18 Years | N/A | All | 15 | Phase 2 | Sweden |